title: Is India ready to lead the battle for fair access to medicines?
authors: Lancet Oncology
mesh_terms: D000970:Antineoplastic Agents / Q000191:economics; D001549:Benzamides / Q000191:economics; D016527:Drug Costs; D004345:Drug Industry / Q000191:economics / Q000331:legislation & jurisprudence*; D004335:Drug and Narcotic Control / Q000191:economics / Q000331:legislation & jurisprudence*; D016568:Drugs, Generic / Q000191:economics; D033161:Government Regulation; D006291:Health Policy / Q000191:economics / Q000331:legislation & jurisprudence*; D006297:Health Services Accessibility / Q000191:economics / Q000331:legislation & jurisprudence*; D006801:Humans; D000068877:Imatinib Mesylate; D007194:India; D009536:Niacinamide / Q000031:analogs & derivatives / Q000191:economics; D010330:Patents as Topic / Q000331:legislation & jurisprudence*; D010671:Phenylurea Compounds / Q000191:economics; D010879:Piperazines / Q000191:economics; D011743:Pyrimidines / Q000191:economics; D000077157:Sorafenib
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D016568:Drugs, Generic; D010671:Phenylurea Compounds; D010879:Piperazines; D011743:Pyrimidines; D009536:Niacinamide; D000068877:Imatinib Mesylate; D000077157:Sorafenib